Dr. Hector Torres-Gomez

Konzeption, Design und Leitung eines translationalen Early-Stage-Wirkstoffforschungsprogramms, unter Integration wissenschaftlicher Validierung, medicinal-chemistry-Strategie, IP- und Freedom-to-Operate-Analyse sowie Fördermittel-Readiness.

Leitung funktionsübergreifender Programme in den Bereichen Neurodegeneration, Onkologie und metabolische Erkrankungen in EU-US-Teams. Direkte Verantwortung in einem Partnerprogramm (NovoNordisk) für die Validierung Leitstrukturen; Auslösung einer Meilensteinzahlung. Beitrag zu patentfähiger chemischer Substanzklasse ein ZNS-Programm erreichte den Status „Development Candidate“. Schnittstellenfunktion zu Business Development, CRO-Steuerung und Portfoliomanagement.

Entwicklung einer Backup-Substanzserie für den Phase-II-Tuberkulosekandidaten BTZ-043 sowie Erweiterung des Antiinfektiva-Portfolios. Beratung akademischer Gruppen im Technologietransfer; Mitwirkung an einer Patentanmeldung aus translationaler Zusammenarbeit (derzeit präklinisch validiert). Mitwirkung an erfolgreicher BMFTR-Förderung und Leitung öffentlich geförderter Verbundprojekte.

Design and synthesis of small molecules addressing multiple Epigenetic Targets. Responsible for the practical course and seminars of Organic Chemistry for Pharmacy undergraduate students, which includes leading a small team of doctoral students that assist in both the practical course and the seminars.

Responsible of a project related to the Design and Synthesis of Antiparasitic compounds and a project related to the pharmackinetics and UPLC-MS/MS quantification and idetification of molecules of synthetic and natural origin

The aim of this work is the development of a new class of highly selective σ2 receptor ligands, using the rigid propellane scaffold to fix the three-dimensional orientation of the pharmacophoric elements to each other. The new compounds should show high σ2 affinity and high selectivity over the σ1 subtype and related receptors.

I was involved in the stereoselective synthesis of b2-tryptophan. The project included the 1,4- addition of (S)-phenylethylamine to a alpha,beta insaturated system and its posterior enzimatic resolution. The results of this project are not yet published.

Lecturer of Organic Chemistry for students of Biochemical Engineering.

Master's project. A series of new dual PPAR alpha/gamma agonists were designed under the molecular hydridization concept, The new molecules have the potential of working as dual PPAR alpha/gamma agonists and could be interesting for the therapeutics of metabolic syndrome. Some structures of this project are already published but the main results are to be published within this year.

As an assistant lecturer I was in charge of teaching selected topics to the undergraduate students and also for the problem workshops

A series of ten novel hybrids from benzimidazole and pentamidine were prepared using a short synthetic route. Each compound was tested in vitro against the protozoa T. vaginalis, G. lamblia, E. histolytica, L. mexicana, and P. berghei. Some analogues showed high bioactivity in the low micromolar range (IC50 < 1 μM) against the first four protozoa, which make them significantly more potent than either standard.

Medicinal Chemistry, Organic Synthesis, Stereoselective Synthesis, Pharmacology, Radio receptor binding assays.

Medicinal Chemistry, Drug Desig, Pharmacology, Metabolic Syndrome, Metabolic Diseases Organic Synthesis, Molecular Pharmacology

Chemistry, Organic Chemistry, Biochemistry, Pharmacology, Medicinal Chemistry